Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (6674)	7/14/1998 11:50:00 AM
From: Robert S.	Read Replies (3) \| Respond to of 17367

<I would have to agree with the possibility of bacteria evolving, but as long as they are coated with a lippid protein sheath, BPI will bind and even if it does not kill the bacteria, it will neutralize the endotoxins, thus relieving the body (and treating physicians) of the need to worry about septic shock. This is important in a disease like meningitis, where the body, with antibiotics, can eventually overcome the disease, but the septic shock kills or cripples the victim.> George, however, earlier stated this: < I never thought BPI bound up all endotoxin. This is dead material and it is not reproducing. The body may/will remove some with its own host defenses and while the remaining endotoxin will do damage I thought that it would be reduced relative to the amount that would have occurred in none was bound up and eliminated by BPI.> It appears, from the above, that some endotoxins will be free to undertake their destructive actions upon the patient. While I regret the circular reasoning, it is unclear to me how BPI will be beneficial if it does not eradicate ALL the endotoxins and/or bacteria (since they evolve) within a patient. What am I missing?